Stoke Therapeutics Inc (STU:0GT)
€ 11 0 (0%) Market Cap: 579.33 Mil Enterprise Value: 320.90 Mil PE Ratio: 0 PB Ratio: 2.60 GF Score: 36/100

Stoke Therapeutics Inc at Needham Neuroscience Forum (Virtual) Transcript

Mar 15, 2023 / 05:20PM GMT
Release Date Price: €8.4 (-7.18%)
Joey Stringer
Needham & Company - Analyst

Good afternoon, everyone. Thank you for joining the Second Annual Needham Neuroscience Forum. My name is Joey Stringer, and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, Stoke Therapeutics. Joining us today from Stoke is CEO, Ed Kaye; and CMO, Barry Ticho. (Conference Instructions)

Questions & Answers

Joey Stringer
Needham & Company - Analyst

So with that, we'll go ahead and get started. Ed and Barry, thank you so much for joining us today. Given that this is a neuroscience forum, we'll start with some high-level industry questions and then we'll get into more company-specific programs.

So it's been said many times that neuroscience is going through a renaissance. What do you believe has been the most important successes to date? And where do you believe more progress needs to be made?

Ed Kaye
Stoke Therapeutics, Inc. - CEO and Director

Well, I think it's always interesting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot